Group items tagged

Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU Commission proposal. An agreement, in principle, has been reached by the UK and EU. The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom. Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result. However, the burden on the UK Pharma supply chain will be eased. Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023 Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products within the Northern Ireland market. Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee the supply of medicines within the whole United Kingdom.

In a delightful announcement, the University of Brighton has honoured NHS England's Chief Pharmaceutical Officer, David Webb with its prestigious Doctor of Science honorary degree Webb's award is a highlight of the university's graduation ceremony which celebrated the graduation of over 3,400 undergraduate and postgraduate students from 92 countries at the Brighton Centre this week. The accolade recognises Webb's transformative work in the pharmacy services within the NHS, highlighting the profound impact his contributions have had on delivery of healthcare across the UK. Under Webb's leadership, significant advancements have been made in integrating pharmacy into NHS care pathways, improving patient outcomes, and enhancing the role of pharmacists and pharmacy technicians in the healthcare system. Webb expressed his honour stating, "I am delighted to receive the honorary award of Doctor of Science from the University of Brighton in recognition of both my contribution to pharmacy in the NHS"

The Royal Pharmaceutical Society (RPS) has appointed Dr Amira Guirguis as the new Chair of its Science and Research Committee, effective from the New Year. An accomplished pharmacist and renowned expert in substance misuse, Dr Guirguis was nominated by the RPS as a 'woman to watch' in 2020. Previously, she has served as the Principal Investigator for the first Home Office-licensed Pharmacist-led drug checking service in the UK, and as the MPharm Programme Director at Swansea University Medical School. A PhD in Novel Psychoactive Substances (NPS) detection, she has made significant contributions to the field of pharmacy, to drug policy, and has won the 2014 JPAG Geoffrey Phillips award for her groundbreaking research.

Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations. Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain. The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care. It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients. In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.

YouGov polling commissioned by the Pharmaceutical Services Negotiating Committee (PSNC) has revealed that majority of the people responding to the poll said that they would be concern by the pharmacy closure in their locality. The results show the extent of the public backing for a Pharmacy First approach - PSNC has been arguing that a fully-funded service would be beneficial for pharmacies, patients and the wider NHS. The poll witnessed 1,774 adults' participation from England. It showed 68 per cent of people agree that they would find it easier to seek health advice for common conditions, such as skin conditions or indigestion, at a community pharmacy rather than a GP surgery. Only 11 per cent disagreed that this would be easier. While 75 per cent of people agree that they would like to see community pharmacies offering more healthcare services such as treating urinary tract infections or sore throats. Only 6 per cent strongly disagreed with this. When asked how important, if at all, are the services provided by community pharmacies to them, their family, or community, 78 per cent indicted this was very important. Only 14 per cent said this wasn't important. 77 per cent said they would be very concerned if the pharmacy they use most often were to close permanently. Only 19 per cent said they would not be very concerned.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England. The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this September. The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training. The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026, all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees. Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical competence. Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".

In its response to a Freedom of Information Request (FOI), the NHS Business Services Authority (NHSBSA) has confirmed a net decrease of 101 pharmacies in England - with 371 closures and 270 new contracts. Meanwhile, the General Pharmaceutical Council data projected a drop of 43 registered pharmacies in England, Wales, and Scotland for the year ending March 31, 2023, compared to the preceding period. The data, released by business advisor Christie & Co in its annual pharmacy market review on Sept. 5, revealed a total of 14,328 pharmacies across all four UK country regions as of March 31, 2023, indicating a 0.3 per cent decrease from the previous year. Corporate operators experienced a net reduction of 249 pharmacies, while the total number of independent operators remained consistent with 2022. According to the study, the corporate sector saw the most substantial shift, with a 13.7 per cent reduction in businesses operating 300 or more pharmacies. Following closely, groups managing 11 to 15 pharmacies experienced a 5.6 per cent decrease. Christie & Co attributed this shift in group size to operators acquiring additional pharmacies through corporate disposal opportunities throughout the year.

The Pharmaceutical Services Negotiating Committee (PSNC) has shared materials to help community pharmacy in communicating relevant advice to people during this heatwave. The UK Health Security Agency (UKHSA) has issued a heat-health alert for the next few days. It has also published a beat the heat poster, along with its heatwave guidance, which could be used in pharmacies to raise awareness. "During this heatwave, the public may turn to community pharmacy teams for advice about staying well during the hot weather or to seek assistance when feeling unwell because of the heat," PSNC said. It has previously developed materials that may be used by community pharmacy teams to communicate relevant messages contained in the Heatwave Plan for England and the NHS website guidance on how to cope in hot weather.

The Pharmaceutical Services Negotiating Committee (PSNC) has appointed Sunil Kumar, an independent contractor from Darlington, as the Regional Representative for the North East and Cumbria region. "Kumar will represent all independent contractors in the region at the PSNC Committee until 31st March 2023, which is the end of the current term for all Regional Representatives," said PSNC. PSNC's North East and Cumbria region covers the areas of Community Pharmacy County Durham; Community Pharmacy Cumbria; Gateshead & South Tyneside LPC; North of Tyne LPC; Sunderland LPC and Tees LPC.

More than 9,300 pharmacy contractors would benefit from earlier advance payment in February, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their January 2022 FP34C submission figures through the Manage Your Service (MYS) portal by February 5 will receive earlier advance payments by today (February 10). The statistics indicates nearly 2,000 contractors will not receive any earlier advance payment this month, either because their January declarations were submitted late or they used the paper FP34C submission document to make their declaration, PSNC said. These contractors will receive their advance payments in accordance with the normal payment timetable i.e. on March 1. The negotiator reminded contractors that from April 2022 MYS will be the only process to make monthly submissions.

Leading health and beauty retailer Superdrug on Monday announced that it has selected on-demand delivery network Gophr to provide its pharmacy delivery service, following a rigorous Request for Information (RFI) process. This means Gophr will be responsible for delivering prescriptions across the UK to people who choose Superdrug to provide their medication. Superdrug's decision to choose Gophr was influenced significantly by the latter's strong Standard Operating Procedures (SOP), its adept ability to track and trace all home deliveries digitally from store to door, and its commitment to offering a best-in-class doorstep experience. According to the retailer, multiple layers of protection are implemented during delivery to uphold standards, ensuring that prescription medicines are handed directly to the intended recipients. Graham Smith, strategic account director at Gophr, highlighted the growing importance of pharmaceutical delivery, especially as pharmacists are now able to provide even more services under Pharmacy First scheme.

"Raise awareness of pharmacies as places of primary health care provision," advocates the International Pharmaceutical Federation (FIP), emphasising the need for universal recognition of pharmacists as essential healthcare professionals. Despite significant advancements in pharmacy practice, many policymakers and members of the public still view pharmacies primarily as commercial enterprises rather than essential providers of healthcare services. The FIP is leading a campaign to change this perception, advocating for pharmacies to be recognised as vital components of primary health care. Primary health care is crucial for achieving "health for all." In 2018, the Declaration of Astana saw governments recommit to strengthening primary health care to achieve universal health coverage. FIP, a signatory to this declaration, has since been dedicated to enhancing the role and impact of pharmacies in primary health care.

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

The Royal Pharmaceutical Society (RPS) Wales has welcomed proposals from the Welsh government to increase access to PrEP via community pharmacies for people at risk of HIV. The new HIV Action Plan for Wales consultation proposes a shared care model between primary care and specialist sexual health services to improve access to PrEP. Commenting on the proposal, chair of RPS in Wales Cheryl Way said: "Increasing access to the medicines has been a long-standing issue of concern for us at RPS and we're therefore delighted to see the proposals outlined by the Welsh government to develop a model which will enable PrEP to be provided by community pharmacies across Wales. "PrEP are highly effective medicines, that reduce the chances of getting HIV, as proven by the Welsh Government's three year PrEPARED study which found no new diagnoses of HIV among over 1,200 people taking PrEP in Wales. This is clear evidence that PrEP should be made as easily accessible as possible to those who need it.

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

From July 2022, Manage Your Services (MYS) portal will be the only route available for pharmacy contactors to submit all new prescription returns/referred back items and disallowed items, reminded the Pharmaceutical Services Negotiating Committee (PSNC). Contractors will be able to view and submit the required information for all these items only through the MYS portal. The NHS Business Services Authority (NHSBSA) will send out a notification email from July (for the dispensing month of June) to the pharmacy NHSmail account if any new referred back or disallowed items have been generated for the contractor to complete on their MYS account. "Contractors can view any referred back items for completion by checking the 'Unpaid items' tab on MYS landing page," PSNC. "It is important to note that prescription returns/referred back items via MYS are only held in the system for a period of 18 months from the date they are first sent to the pharmacy for action; if contractors have not completed and returned any outstanding referred backs before this deadline has passed, the referred back items will be deleted from system."

Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director. Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis. For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research Organisation. In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry. Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market."

Buy Votrient 200 Mg Pazopanib Hydrochloride Tablets India-Russia , Votrient-200Mg is not a chemotherapy drug but one of many "targeted therapies." Targeted therapy is the result of about 100 years of research dedicated to understanding the differences between cancer cells and normal cells. We are leading suppliers & exporters of "Votrient 200Mg" in China, Russia, Hongkong, Bulgaria, Romania, India, UK, USA. We're largest suppliers of Glaxo Smith Kline medicines & provide you the best price on Votrient. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Buy Votrient 200 Mg Pazopanib Hydrochloride Tablets India Votrient 200Mg Suppliers India Pazopanib is used to treat kidney cancer. It may also be used to treat certain other types of cancer (soft tissue sarcoma). Pazopanib belongs to a class of drugs known as Tyrosine Kinase Inhibitors. It works by decreasing the blood supply to the cancer tumor to slow tumor growth. VOTRIENT may shrink or slow the growth of the cancer by interfering with the function of a protein called vascular endothelial growth factor. It is used to treat adults with metastatic renal cell carcinoma, a form of kidney cancer.. Itmay shrink or slow the growth of kidney cancer for a period of time. we are leading suppliers & exporters of Votrient 200Mg Pazopanib Hydrochloride Tablet in China, Russia, Hongkong, Bulgaria, Romania, India, UK, USA and many more And the largest suppliers-exporters of "Glaxo smith Kline" medicines & provide you the best price on Votrient 200Mg Pazopanib Hydrochloride Tablet. The lowest price sellers, suppliers, distributors & Exporters from Delhi For More Info Please Contact us. Brand Name - Votrient Generic - Pazopanib Hydrochloride Strength - 200 Mg Form - Tablets Packing - 1 X 30 Manufactured by - Glaxo smith Kline Warning: Votrient 200Mg medicine out of the reach and sight of children and away from pets, never share your medic

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."